Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction
NCT01856127Phase 4Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vilazodone in major depressive disorder (MDD) (2 arms), sponsored by Thomas Jefferson University. Primary endpoint: Changes in Sexual Functioning Questionnaire at 11 weeks. Started Jan 2013; status: terminated.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01856127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856127.